Food noise is the constant, unwanted chatter about food: what to eat next, whether you should, how much, and when, loud enough that it crowds out other thinking. Researchers now define it as "persistent thoughts about food that are perceived by the individual as being unwanted and/or dysphoric", set apart from ordinary thoughts about lunch "by its intensity and intrusiveness, resembling rumination."3 GLP-1 medicines such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are the reason the phrase spread, because so many people who take them say it went quiet.
The short verdict: people on these medicines consistently report much less food noise, and the one controlled trial that measured something close to it (cravings) agrees. What does not exist yet is a randomised trial with food noise itself as the outcome, and nobody has followed what happens to it after people stop. This page sets out what is measured, by whom, and what it costs to try.
What food noise is, in the researchers' words
The term came from patients before it came from science. By 2025 an Indiana University group had written a formal definition, and described the experience as "constant preoccupation with food-related decisions-such as which foods to eat, caloric intake, macronutrient balance, and meal timing-which can become intrusive and unpleasant."3
A second definition, built on how strongly people react to food cues, describes it as "heightened and/or persistent manifestations of food cue reactivity, often leading to food-related intrusive thoughts and maladaptive eating behaviors."6 Both point the same way: food noise is not hunger. Hunger is a body signal that a meal answers. Food noise is thinking that carries on after the meal.
| Ordinary hunger | Food noise | |
|---|---|---|
| What it is | A body signal that it is time to eat | Persistent, unwanted thoughts about food3 |
| Does eating stop it? | Usually, for a while | Often not: it is about decisions, rules and cues, not an empty stomach |
| How researchers describe it | Appetite, satiety | Intensity and intrusiveness "resembling rumination"3 |
| How it is measured | Hunger rating scales | The five-item Food Noise Questionnaire, scored 0 to 2024 |
How common it is
The first nationally representative estimate was published in October 2026. In a survey of 1,000 US adults taken in May 2026, "50.89% of respondents reported experiencing food noise at least occasionally and 17.98% frequently."1 Frequent food noise was more common in women (22.70% against 12.68% in men) and in current and former GLP-1 users (25.76% and 26.78% against 16.30% of non-users). The strongest predictor was loss of control over eating, with an odds ratio of 5.95.1
Read the GLP-1 figure with care: it is a snapshot, so it cannot say whether the medicine raised or lowered anything. People with the most food noise may simply be the ones who seek out a GLP-1.
How food noise is measured
Until 2025 there was no validated way to score it: the authors of the first tool wrote that "no validated questionnaires exist to measure it."2 Their Food Noise Questionnaire (FNQ) was tested on 400 people, and "the five FNQ items loaded onto a single factor", meaning the five questions measure one thing.2 It is scored out of 20. The same paper adds that "further research is needed to evaluate its clinical utility", and four of its authors worked for or held shares in WW International.2
The Indiana group built a separate tool, the RAID-FN Inventory, alongside their definition.3 Two instruments in two years is a sign of how new the field is: most of the numbers below come from the FNQ.
What GLP-1s do to food noise: the evidence, strongest first
| Study | Design | Who | What it found | Limits |
|---|---|---|---|---|
| Blundell 20175 | Randomised, double-blind, placebo-controlled crossover, 12 weeks | 30 adults with obesity, semaglutide up to 1.0 mg | "less hunger and food cravings, better control of eating"; 24% less energy eaten at test meals | Small, short; measured cravings, not food noise by name; Novo Nordisk co-authors |
| INFORM survey 20264 | One-off survey, recalled "before" score | 550 US adults on injectable semaglutide, 81% for at least 4 months | Median FNQ 13 of 20 before, 6 after; agreement with food noise statements fell from 47-63% to 15-20% | Memory of "before", self-selected panel, no comparison group; funded by Novo Nordisk |
| Stanford interviews 20267 | Qualitative, 30 interviews | Current and former GLP-1 users in 15 states | First theme: "reduction in food noise, psychological hunger, or appetite" | Describes experience, does not measure size |
| TikTok content study 20266 | Analysis of the top 100 #FoodNoise videos | Mostly patient testimonies (70.71%) | Half the videos (49.49%) mentioned medicines, mainly GLP-1s | Shows what people say online, not what the drug does |
Put together: the direction is consistent and the size reported by users is large, a drop of about half on the questionnaire. The quality is the weak point. The biggest food noise number comes from a manufacturer-funded survey that asked people to remember how they felt before, and its own authors write that "further prospective, longitudinal research is warranted."4 The only randomised data are on cravings, from 30 people over 12 weeks.5
Why it happens: what the labels say
The prescribing information explains the appetite side, not food noise as such. Wegovy's label: "GLP-1 is a physiological regulator of appetite and caloric intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation", and "Semaglutide decreases calorie intake. The effects are likely mediated by affecting appetite."9
Zepbound's label says the same about GLP-1 and adds the second hormone tirzepatide copies: "Nonclinical studies suggest the addition of GIP may further contribute to the regulation of food intake. Both GIP receptors and GLP-1 receptors are found in areas of the brain involved in appetite regulation." It also states: "Tirzepatide decreases calorie intake. The effects are likely mediated by affecting appetite."10
We found no published study scoring food noise on tirzepatide specifically. The labels describe the same appetite mechanism for both, so the patient reports are not surprising, but a head-to-head on food noise does not exist. Our tirzepatide vs semaglutide guide covers the weight-loss trials that do compare them.
What happens to food noise when you stop
No study we found has followed food noise after people stop a GLP-1. What is measured is weight. In the STEP 1 extension, people lost 17.3% of their weight on semaglutide over 68 weeks, and "One year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss".12
The Stanford participants framed the medicine as "a facilitator rather than a replacement for lifestyle change", and stressed "the need for behavioral interventions alongside pharmacotherapy to sustain treatment benefits."7 Our guide to stopping a GLP-1 and weight regain covers the stopping trials in full. The practical point for food noise: plan the habits you want to keep while it is quiet, and talk to your prescriber before you stop.
When quieter is not better
Food noise overlaps with eating disorders, and that cuts both ways. An eating disorders journal spotlight in 2026 wrote that GLP-1s "may hold therapeutic promise for some individuals with binge eating disorder or loss-of-control eating, but the same mechanisms that reduce appetite and food preoccupation may also reinforce restriction, avoidance of regular eating, compulsive weight control, and relapse in vulnerable individuals." Its first recommendation is "routine eating disorder screening before and during GLP-1 RA treatment".8
If you have had an eating disorder, tell the prescriber before you start, and tell them if not wanting to eat starts to feel like a rule rather than relief. A program that never asks about it is skipping a step the specialists now call routine.
What it costs to try
None of these medicines is approved to treat food noise; they are prescribed for weight or blood sugar, and a clinician decides whether you qualify. If you do, the cheapest cash route on our board today is $69 a month for compounded semaglutide, with compounded tirzepatide from $85 and the middle program at $158. The FDA notes that "compounded drugs are not FDA approved"11; our telehealth programs guide covers what the monthly price includes and the red flags to check.
For a single medicine, the ranked lists are at cheapest semaglutide and cheapest tirzepatide, both checked against the sellers' own pages.
